Heyman Richard A. — SEC insider filings
SEC reporting owner CIK 1584759. 60 insider filings on record with FilingPulse; latest filed 2026-10-02.
Transaction summary — filings shown
Covers the 50 most recent of 60 filings on record, filed 2021-06-04 to 2026-10-02. Counts and totals are arithmetic on values as filed — descriptive data, not a recommendation.
- Open-market purchases (code P, non-derivative): none reported.
- Open-market sales (code S, non-derivative): 45 legs across 26 filings — 76,888 shares, $1,504,069 total (shares × price as filed).
- Other reported legs (grants, option exercises, tax withholding, gifts, derivative-security transactions, …): 35.
- Largest priced transaction: sale of 8,015 shares @ $25.04 ($200,656) in Enliven Therapeutics, Inc., filed 2026-01-12.
By issuer — same filings
Open-market purchase/sale legs on non-derivative securities, grouped by issuer. Role is as filed on the newest filing for that issuer. Dollar totals cover priced legs only (shares × price as filed). Ordered by priced transaction value, largest first.
| Issuer | Role (as filed) | Filings | Purchases (P) | Sales (S) | Other legs |
|---|---|---|---|---|---|
| Enliven Therapeutics, Inc. (ELVN) | Director | 25 | — | 33 legs · 46,534 sh · $1,086,964 | 9 |
| Oric Pharmaceuticals, Inc. (ORIC) | Director | 14 | — | 12 legs · 30,354 sh · $417,105 | 15 |
| PMV Pharmaceuticals, Inc. (PMVP) | Director | 6 | — | — | 6 |
| Gritstone bio, Inc. (GRTS) | Director | 2 | — | — | 2 |
| Metacrine, Inc. (MTCR) | Director | 1 | — | — | 1 |
| RayzeBio, Inc. (RYZB) | Director | 1 | — | — | 1 |
| YUMANITY THERAPEUTICS, INC. (YMTX) | Director | 1 | — | — | 1 |
Insider filings — Heyman Richard A.
| Filed | Form | Issuer | Reported transactions | Source |
|---|---|---|---|---|
| 2026-10-02 | 4 | Oric Pharmaceuticals, Inc. (ORIC) | Option exercise (M): 3,500 @ $1.60 · Sale (S): 3,500 @ $12.91 · Sale (S): 3,200 @ $12.91 · Option exercise (M): 3,500 (derivative) @ $0 | EDGAR |
| 2026-07-28 | 4 | Oric Pharmaceuticals, Inc. (ORIC) | Option exercise (M): 3,500 @ $1.60 · Sale (S): 7,000 @ $12.02 · Sale (S): 6,100 @ $12.02 · Option exercise (M): 3,500 (derivative) @ $0 | EDGAR |
| 2026-07-08 | 4 | Oric Pharmaceuticals, Inc. (ORIC) | Sale (S): 300 @ $12 | EDGAR |
| 2026-02-19 | 4 | Enliven Therapeutics, Inc. (ELVN) | Sale (S): 1,230 @ $26.18 | EDGAR |
| 2026-02-17 | 4 | Enliven Therapeutics, Inc. (ELVN) | Grant/award (A): 19,234 (derivative) @ $0 | EDGAR |
| 2026-01-22 | 4 | Enliven Therapeutics, Inc. (ELVN) | Sale (S): 512 @ $26.46 · Sale (S): 718 @ $26.96 | EDGAR |
| 2026-01-20 | 4 | Oric Pharmaceuticals, Inc. (ORIC) | Sale (S): 3,500 @ $12.00 · Sale (S): 3,200 @ $12.00 | EDGAR |
| 2026-01-12 | 4 | Enliven Therapeutics, Inc. (ELVN) | Sale (S): 1,620 @ $25 · Sale (S): 8,015 @ $25.04 · Sale (S): 4,285 @ $25.00 | EDGAR |
| 2026-01-06 | 4 | Oric Pharmaceuticals, Inc. (ORIC) | Grant/award (A): 40,000 (derivative) @ $0 | EDGAR |
| 2025-10-03 | 4 | Oric Pharmaceuticals, Inc. (ORIC) | Option exercise (M): 31,353 @ $1.60 · Option exercise (M): 1,447 @ $3.75 · Option exercise (M): 13,228 (derivative) @ $0 · Option exercise (M): 18,125 (derivative) @ $0 · Option exercise (M): 1,447 (derivative) @ $0 | EDGAR |
| 2025-06-09 | 4 | PMV Pharmaceuticals, Inc. (PMVP) | Grant/award (A): 33,500 (derivative) @ $0 | EDGAR |
| 2025-02-10 | 4 | Enliven Therapeutics, Inc. (ELVN) | Grant/award (A): 23,014 (derivative) @ $0 | EDGAR |
| 2025-01-06 | 4 | Oric Pharmaceuticals, Inc. (ORIC) | Grant/award (A): 35,000 (derivative) @ $0 | EDGAR |
| 2024-10-22 | 4 | Enliven Therapeutics, Inc. (ELVN) | Sale (S): 817 @ $30.00 · Sale (S): 753 @ $30.00 | EDGAR |
| 2024-10-17 | 4 | Enliven Therapeutics, Inc. (ELVN) | Sale (S): 1,270 @ $27.67 | EDGAR |
| 2024-10-08 | 4 | Enliven Therapeutics, Inc. (ELVN) | Sale (S): 2,825 @ $27.51 | EDGAR |
| 2024-10-03 | 4 | Enliven Therapeutics, Inc. (ELVN) | Sale (S): 518 @ $27.54 | EDGAR |
| 2024-09-18 | 4 | Enliven Therapeutics, Inc. (ELVN) | Sale (S): 1,270 @ $22.41 | EDGAR |
| 2024-08-19 | 4 | Enliven Therapeutics, Inc. (ELVN) | Sale (S): 650 @ $22.82 · Sale (S): 620 @ $23.70 | EDGAR |
| 2024-08-02 | 4 | Enliven Therapeutics, Inc. (ELVN) | Sale (S): 1,702 @ $27.51 · Sale (S): 649 @ $27.50 | EDGAR |
| 2024-07-17 | 4 | Enliven Therapeutics, Inc. (ELVN) | Sale (S): 1,270 @ $24.80 | EDGAR |
| 2024-06-20 | 4 | Enliven Therapeutics, Inc. (ELVN) | Sale (S): 1,270 @ $21.48 | EDGAR |
| 2024-06-14 | 4 | Oric Pharmaceuticals, Inc. (ORIC) | Grant/award (A): 25,600 (derivative) @ $0 | EDGAR |
| 2024-06-10 | 4 | PMV Pharmaceuticals, Inc. (PMVP) | Grant/award (A): 67,500 (derivative) @ $0 | EDGAR |
| 2024-05-20 | 4 | Enliven Therapeutics, Inc. (ELVN) | Sale (S): 1,270 @ $23.74 | EDGAR |
| 2024-04-15 | 4 | Enliven Therapeutics, Inc. (ELVN) | Sale (S): 5,045 @ $25.03 · Sale (S): 1,190 @ $19.94 · Sale (S): 80 @ $20.68 · Sale (S): 649 @ $25 | EDGAR |
| 2024-03-21 | 4 | Enliven Therapeutics, Inc. (ELVN) | Sale (S): 1,270 @ $14.50 | EDGAR |
| 2024-02-27 | 4 | RayzeBio, Inc. (RYZB) | Disposition to issuer (D): 367,446 @ $62.50 | EDGAR |
| 2024-02-20 | 4/A | Enliven Therapeutics, Inc. (ELVN) | Grant/award (A): 29,205 (derivative) @ $0 | EDGAR |
| 2024-02-20 | 4 | Enliven Therapeutics, Inc. (ELVN) | Sale (S): 1,270 @ $17.42 | EDGAR |
| 2024-02-15 | 4 | Enliven Therapeutics, Inc. (ELVN) | Grant/award (A): 21,043 (derivative) @ $0 | EDGAR |
| 2024-02-01 | 4 | Enliven Therapeutics, Inc. (ELVN) | Sale (S): 1,270 @ $16.41 | EDGAR |
| 2023-12-26 | 4 | Enliven Therapeutics, Inc. (ELVN) | Sale (S): 7 @ $13 · Sale (S): 6 @ $13 · Sale (S): 168 @ $13 · Sale (S): 35 @ $13 | EDGAR |
| 2023-12-21 | 4 | Enliven Therapeutics, Inc. (ELVN) | Sale (S): 255 @ $13 · Sale (S): 2,110 @ $13.02 · Sale (S): 1,915 @ $13.02 | EDGAR |
| 2023-06-15 | 4 | Oric Pharmaceuticals, Inc. (ORIC) | Grant/award (A): 20,500 (derivative) @ $0 | EDGAR |
| 2023-06-12 | 4 | PMV Pharmaceuticals, Inc. (PMVP) | Grant/award (A): 21,500 (derivative) @ $0 | EDGAR |
| 2023-04-06 | 4 | Enliven Therapeutics, Inc. (ELVN) | Grant/award (A): 34,458 (derivative) @ $0 | EDGAR |
| 2023-02-27 | 4 | Enliven Therapeutics, Inc. (ELVN) | Grant/award (A): 149,820 · Grant/award (A): 37,407 · Grant/award (A): 31,172 · Grant/award (A): 20,657 (derivative) | EDGAR |
| 2022-09-06 | 4 | Metacrine, Inc. (MTCR) | Grant/award (A): 16,500 (derivative) @ $0 | EDGAR |
| 2022-06-22 | 4 | Gritstone bio, Inc. (GRTS) | Grant/award (A): 19,000 (derivative) @ $0 | EDGAR |
| 2022-06-17 | 4 | Oric Pharmaceuticals, Inc. (ORIC) | Grant/award (A): 53,700 (derivative) @ $0 | EDGAR |
| 2022-06-06 | 4 | PMV Pharmaceuticals, Inc. (PMVP) | Grant/award (A): 19,500 (derivative) @ $0 | EDGAR |
| 2021-11-19 | 4 | Gritstone bio, Inc. (GRTS) | Grant/award (A): 19,000 (derivative) @ $0 | EDGAR |
| 2021-09-16 | 4 | Oric Pharmaceuticals, Inc. (ORIC) | Sale (S): 706 @ $25.05 · Sale (S): 682 @ $25.03 | EDGAR |
| 2021-09-14 | 4 | Oric Pharmaceuticals, Inc. (ORIC) | Sale (S): 479 @ $25.10 · Sale (S): 601 @ $25.01 | EDGAR |
| 2021-09-09 | 4 | Oric Pharmaceuticals, Inc. (ORIC) | Sale (S): 1,086 @ $25.11 | EDGAR |
| 2021-07-23 | 4 | PMV Pharmaceuticals, Inc. (PMVP) | Grant/award (A): 5,781 (derivative) @ $0 | EDGAR |
| 2021-06-17 | 4 | Oric Pharmaceuticals, Inc. (ORIC) | Grant/award (A): 16,625 (derivative) @ $0 | EDGAR |
| 2021-06-09 | 4 | PMV Pharmaceuticals, Inc. (PMVP) | Grant/award (A): 16,333 (derivative) @ $0 | EDGAR |
| 2021-06-04 | 4 | YUMANITY THERAPEUTICS, INC. (YMTX) | Grant/award (A): 14,800 (derivative) @ $0 | EDGAR |
FilingPulse's Form 4 archive currently extends back to 2020-11-05 and is expanding backward through EDGAR history; Forms 3 and 5 are covered live-forward since 2026-09-23 (no 3/5 history). Earlier filings by this insider may not be indexed yet. Names and roles are shown as filed.
GET https://api.filingpulse.io/v1/insider-trades?owner_cik=1584759 returns every filing on this page — normalized, with footnotes and derivative legs — and webhooks push new filings to you in seconds. Get a free API key → · API docs